ECG abnormalities in co-proxamol (paracetamol/dextropropoxyphene) poisoning

Clinical Toxicology

Volumn 43, Issue 4, 2005, Pages 255-259

  Afshari, R ^a   Maxwell, S ^b   Dawson, A ^c   Bateman, D N ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c NEWCASTLE MATER HOSPITAL   (Australia)

Author keywords

Co proxamol; Dextropropoxyphene; ECG changes; Opioids; Poisoning

Indexed keywords

COCODAMOL; CODYDRAMOL; DEXTROPROPOXYPHENE; DEXTROPROPOXYPHENE PLUS PARACETAMOL; OPIATE; PARACETAMOL;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG INTOXICATION; ECG ABNORMALITY; FEMALE; HUMAN; MALE; QRS COMPLEX;

ACETAMINOPHEN; ADULT; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; CODEINE; DRUG COMBINATIONS; ELECTROCARDIOGRAPHY; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; MALE; OVERDOSE; PROPOXYPHENE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

ANIMALIA;

EID: 23044510818     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.1081/CLT-200066069     Document Type: Article

References (29)

1. Hawton K, Simkin S, Decks J. Co-proxamol and suicide: a study of national mortality statistics and local non-fatal self poisonings. BMJ 2003; 326:1006-1008.
2. Bateman DN. Opioids. Medicine the Continously Updated Resource of Clinical Medicine. The Medicine Publishing Company Ltd., 2003:64-66.
3. Bateman DN, Afshari R. Co-proxamol and suicide: licence needs to be changed. BMJ 2003; 327:287.
4. British National Formulary. 45th ed. London: British Medi cal Association and the Royal Pharmaceutical Society of Great Britain, 2003.
5. Schiodt FV, Ott P, Christensen E, Bondesen S. The value of plasma acetaminophen half-life in antidote-treated acetaminophen overdosage. Clin Pharmacol Ther 2002; 71:221-225.
6. British National Formulary. 45th ed. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2003.
7. Nickander RC, Emmerson JL, Hynes MD, Steinberg MI, Sullivan HR. Pharmacologic and toxic effects in animals of dextropropoxyphene and its major metabolite norpropoxyphene: a review. Human Toxicol 1984; 3(suppl):13S-36S.
8. Whitcomb DC, Gilliam FR III, Starmer CF, Grant AO. Marked QRS complex abnormalities and sodium channel blockade by propoxyphene reversed with lidocaine. J Clin Invest 1989; 84:1629-1636.
9. Holland DR, Steinberg MI. Electrophysiologic properties of propoxyphene and norpropoxyphene in canine cardiac conducting tissues in vitro and in vivo. Toxicol Appl Pharmacol 1979; 47:123-133.
10. Amsterdam EA, Rendig SV, Henderson GL, Mason DT. Depression of myocardial contractile function by propoxyphene and norpropoxyphene. J Cardiovasc Pharmacol 1981; 3:129-138.
11. Hondeghem LM, Katzung BG. Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim Biophys Acta 1977; 472:373-398.
12. Bredgaard SM, Strom J, Sloth MP, Angelo HR, Reiz S. Haemodynamic, electrocardiographic and cardiometabolic changes after overdose of propoxyphene. An experimental study in pentobarbitone-anaesthetized pigs. Human Toxicol 1984; 3(suppl):53S-59S.
13. Bredgaard SM, Haggmark S, Nyhman H, Sloth MP, Strom J, Reiz S. Circulatory shock following intravenous propoxyphene poisoning. An experimental study of cardiac function and metabolism in pentobarbital-anesthetized pigs. Acta Anaesthesiol Scand 1985; 29:130-136.
14. Lund-Jacobsen H. Cardio-respiratory toxicity of propoxyphene and norpropoxyphene in conscious rabbits. Acta Pharmacol Toxicol (Copenh) 1978; 42:171-178.
15. Stork CM, Redd JT, Fine K, Hoffman RS. Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate-a case report. J Toxicol, Clin Toxicol 1995; 33:179-183.
16. Afshari R, Bateman DN. ECG abnormalities in co-proxamol (paracetamol/dextropropoxyphene) poisoning. J Toxicol, Clin Toxicol 2003; 41.
17. Proudfoot AT. Clinical features and management of distalgesic overdose. Human Toxicol 1984; 3(suppl):85S-94S.
18. Buckley BM, Vale JA. Dextropropoxyphene poisoning: problems with interpretation of analytical data. Human Toxicol 1984; 3(suppl):95S-101S.
19. Rodda BE, Scholz NE, Gruber CM Jr, Wolen RL. Evaluation of plasma concentrations of propoxyphene utilizing a hybrid principal component-analysis of variance technique. Case 1-equimolar doses. Toxicol Appl Pharmacol 1971; 19:554-562.
20. Verebely K, Inturrisi CE. Disposition of propoxyphene and norpropoxyphene in man after a single oral dose. Clin Pharmacol Ther 1974; 15:302-309.
21. Schou J, Angelo H, Dam W, Jensen K, Christensen JM. Pharmacokinetics of dextropropoxyphene in acute poisoning. Arch Toxicol 1978; 1:343-346.
22. Pearson RM. Pharmacokinetics of propoxyphene. Human Toxicol 1984; 3(suppl):37S-40S.
23. Crome P, Gain R, Ghurye R, Flanagan RJ. Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in elderly hospital patients after single and multiple doses of distalgesic. Preliminary analysis of results. Human Toxicol 1984; 3(suppl):41S-48S.
24. Gram LF, Schou J, Way WL, Heltberg J, Bodin NO. d-Propoxyphene kinetics after single oral and intravenous doses in man. Clin Pharmacol Ther 1979; 26:473-482.
25. Ansel GM, Coyne K, Arnold S, Nelson SD. Mechanisms of ventricular arrhythmia during amitriptyline toxicity. J Cardiovasc Pharmacol 1993; 22:798-803.
26. Lavoie FW, Gansert GG, Weiss RE. Value of initial ECG findings and plasma drug levels in cyclic antidepressant overdose. Ann Emerg Med 1990; 19:696-700.
27. Niemann JT, Bessen HA, Rothstein RJ, Laks MM. Electrocardiographic criteria for tricyclic antidepressant cardiotoxicity. Am J Cardiol 1986; 57:1154-1159.
28. Jonasson B, Jonasson U, Saldeen T. Among fatal poisonings dextropropoxyphene predominates in younger people, antidepressants in the middle aged and sedatives in the elderly. J Forensic Sci 2000; 45:7-10.
29. Whittington RM. Dextropropoxyphene deaths: coroner's report. Human Toxicol 1984; 3(suppl):175S-185S.